NICE has recommended further evidence generation for the Genedrive MT-RNR1 ID Kit, a technology developed to detect a genetic variant that guides antibiotic use and prevents hearing loss in babies.
This plan outlines the gaps in evidence for the technology and the real-world data that needs to be collected for a future NICE review. The responsibility for data collection and analysis lies with the technology developer.
Support for evidence generation will be facilitated by the Office for Life Sciences, pending business case approval. This includes funding for evidence generation consortia, bringing together analytical partners, implementation sites, and developers.
Guidance on commissioning and procurement of the technology will be provided by NHS England, who is also developing a digital health technology policy framework.
After 3 years of evidence generation, the developer should submit the evidence to NICE for review and decision making on routine adoption in the NHS.
🌍 How can Egypt’s hepatitis C elimination program inspire other African nations?
Discover how Egypt has set a powerful benchmark for public health excellence through its “100 million Healthier Lives” campaign, achieving Gold-tier certification from the WHO. This article looks into the training initiatives and regional collaboration that are paving the way for health improvements across the continent.
#SyenzaNews #GlobalHealth #HealthcareInnovation #Innovation #HealthForAll
🌍 How do robust regulatory systems impact public health globally?
Senegal and Rwanda have made significant strides by achieving WHO Maturity Level 3 in medicines regulation, enhancing their capability to ensure safe and effective medical products. This accomplishment not only fortifies local health standards but also sets a benchmark for other nations to follow, promoting regional collaboration and economic benefits. Discover how this achievement will impact global health outcomes!
#SyenzaNews #globalhealth #regulatoryaffairs #MarketAccess #innovation
🌍 How close are we to achieving the **95-95-95 HIV targets**?
Explore the latest insights from UNAIDS on the progress and strategic importance of these targets in ending the HIV/AIDS pandemic by 2030. The framework not only focuses on comprehensive testing and treatment but also emphasizes equity in healthcare access across all demographics.
Read more about how we can collectively strive for a future free from HIV/AIDS-related stigma and health inequities.
#SyenzaNews #GlobalHealth #HealthcareInnovation #Healthforall #FutureofHealthcare
SPEAK WITH US
CORRESPONDENCE ADDRESS
1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA
WRITE US
JOIN NEWSLETTER
